Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve immunotherapeutic treatment of birch pollen allergy. In a funding round arranged by Springvest Oy, the company raised 4 million euros that it intends to use for funding clinical...Read more »
Below you can find the latest news releases from Desentum.
Desentumin joukkorahoituskierros käynnistyi 17.9.2019Read more »
Preparations are currently being finalized for the first clinical study with DM-101 hypoallergen, Desentum’s lead product candidate for the treatment of birch pollen allergy.Read more »
Desentum has been awarded a 1.9 M€ grant from the EIC pilot SME Instrument for a project titled AllergyVAX. The two-and-a-half-year project, starting at the end of 2018, includes early clinical trials of Desentum’s lead product candidate, an immunotherapeutic vaccine for birch pollen allergy.Read more »
Desentum is progressing towards clinical stage with its first immunotherapeutic product targeting birch pollen allergy. It has raised approx. EUR 2.3 million in a crowd funding campaign arranged by a Finnish investment service company Kansalaisrahoitus. The funds raised in this round will be used...Read more »